Skip to main content

Market Overview

Why Citigroup Placed An $85 Price Target On Shares Of Alkermes


Citigroups' Jonathan Eckard, Ph.D. continues to believe that Alkermes Plc (NASDAQ: ALKS) is a top name among biotech stocks and remains on the Citi U.S. Focus List.

On Wednesday, Eckard increased his price target on Buy-rated Alkermes to $85 from a previous $72, reflecting the belief that the benefits of ALKS-3831 are “clinically meaningful” and open up new avenues of using olanzapine (Zyprexa) in schizophrenia.

“We view ALKS-3831's potential success in the second setting of schizophrenia with alcohol abuse has even stronger scientific rationale and could create an additional commercial opportunity for the drug,” Eckard wrote. “With additional important pipeline data coming over the first half of 2015, we see the potential for additional near-term value inflections for Alkermes shares.”

Eckard adds that ALKS-3831 is a treatment option for patients experiencing significant and rapid weight gain on generic olanzapine, and the potential exists for the treatment to increase patients initiating olanzapine given there is a migration option for the common metabolic effects.

In addition, Eckard sees data from ALKS-7106 (pain) and ALKS-8700 (multiple sclerosis) will receive the most focus from the Street and positive results from just one treatment could provide further upside support to valuation. The analyst also notes that multiple wins could create a “significant value inflection” with shares trading as high as $100 per share.

Latest Ratings for ALKS

Jun 2021HC Wainwright & Co.MaintainsNeutral
Apr 2021HC Wainwright & Co.MaintainsNeutral
Dec 2020SVB LeerinkMaintainsMarket Perform

View More Analyst Ratings for ALKS
View the Latest Analyst Ratings


Related Articles (ALKS)

View Comments and Join the Discussion!

Posted-In: alkermes ALKS 3831 Jonathan Eckard olanzapine zyprexaAnalyst Color Price Target Analyst Ratings

Latest Ratings

ATERRoth CapitalMaintains25.0
FMTXSVB LeerinkMaintains54.0
PLXSLoop CapitalMaintains105.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at